NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: AARTIDRUGS · data 2026-10-30
Aarti Drugs Limited
In plain words
Price: 18.5% below its 52-week high of ₹534.
Delivery: 41.3% of traded shares were kept for delivery over the last 10 sessions, against 47.3% over the last 60.
Latest results: a net profit of ₹50 cr for the quarter ended Jun 2026 (-6.9% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,678 cr |
| Net profit (last 12 months) | ₹191 cr |
| Sales growth, 3 years (yearly) | -2.0% |
| Profit growth, 3 years (yearly) | 5.4% |
Latest results in brief (Q1 FY27)
AARTIDRUGS Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹702.78 crore, up 19% YoY and down 2.4% QoQ.
Net profit was ₹50.17 crore, down 6.9% YoY and down 9.1% QoQ.
Operating margin was 14% (12.5% a year ago).
EPS was ₹5.49, down 7.1% YoY and down 9.3% QoQ.
AARTIDRUGS के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹702.78 करोड़; पिछले साल की तुलना में 19% की बढ़त, पिछली तिमाही की तुलना में 2.4% की गिरावट।
शुद्ध मुनाफ़ा: ₹50.17 करोड़; पिछले साल की तुलना में 6.9% की गिरावट, पिछली तिमाही की तुलना में 9.1% की गिरावट।
ऑपरेटिंग मार्जिन: 14% (एक साल पहले 12.5%)।
EPS: ₹5.49; पिछले साल की तुलना में 7.1% की गिरावट, पिछली तिमाही की तुलना में 9.3% की गिरावट।
AARTIDRUGSના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹702.78 કરોડ; ગયા વર્ષની સરખામણીએ 19% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 2.4% ઘટાડો.
ચોખ્ખો નફો: ₹50.17 કરોડ; ગયા વર્ષની સરખામણીએ 6.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 9.1% ઘટાડો.
ઓપરેટિંગ માર્જિન: 14% (એક વર્ષ પહેલાં 12.5%).
EPS: ₹5.49; ગયા વર્ષની સરખામણીએ 7.1% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 9.3% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 15.0% over the last 20 sessions vs 44.7% in the 40 before (0.34x); shares delivered per day 1.22x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 10/15: Verdict "Building", sustained score 86/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 31 Jul 26Results Q1 FY27 results: profit −6.9% YoY -1.3% next session
- 15 May 26Results Q4 FY26 results: profit −12.2% YoY +1.0% next session
- 9 Feb 26Dividend Dividend ₹2 (ex-date) +1.3% next session
- 3 Feb 26Results Q3 FY26 results: profit +9.4% YoY -3.3% next session
- 7 Nov 25Results Q2 FY26 results: profit +29.3% YoY +6.5% next session
- 18 Jul 25Results Q1 FY26 results: profit +62.2% YoY +5.3% next session
- 12 May 25Results Q4 FY25 results: profit +32.7% YoY +8.3% next session
- 4 Feb 25Dividend Dividend ₹1 (ex-date) -1.8% next session
- 30 Jan 25Results Q3 FY25 results: profit +1.0% YoY +2.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹703 cr | ₹50 cr | -6.9% | 14.0% | 5.49 |
| Mar 2026 | ₹720 cr | ₹55 cr | -12.2% | 13.3% | 6.05 |
| Dec 2025 | ₹602 cr | ₹41 cr | +9.4% | 9.1% | 4.44 |
| Sept 2025 | ₹653 cr | ₹45 cr | +29.3% | 12.9% | 4.95 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 54.07% | 54.43% | 55.03% | 55.03% |
| Foreign institutions (FII) | 2.26% | 1.52% | 1.58% | 2.15% |
| Domestic institutions (DII) | 10.24% | 10.29% | 10.22% | 10.12% |
| Mutual funds | 9.97% | 10.08% | 10.14% | 10.03% |
| Retail investors | 18.30% | 18.75% | 18.13% | 17.85% |
| Number of shareholders | 1,39,949 | 1,43,476 | 1,44,946 | 1,48,363 |
Common questions
What was Aarti Drugs Limited's latest quarterly profit?
Aarti Drugs Limited reported a net profit of ₹50 cr for the quarter ended Jun 2026 (-6.9% on the same quarter a year earlier), on revenue of ₹703 cr.
How much do promoters hold in Aarti Drugs Limited?
Promoters held 54.07% of Aarti Drugs Limited at the end of Sept 2026, with 2.51% of promoter shares pledged.
Is Aarti Drugs Limited debt-free?
Its latest reported debt-to-equity ratio is 0.37.
What is Aarti Drugs Limited's P/E ratio?
About 20.8, based on the last 12 months' earnings and a price of ₹435.2 (data 2026-10-30).
What is the 52-week high and low of Aarti Drugs Limited?
The 52-week high is ₹534 and the 52-week low is ₹318.95.
Similar companies
SMS Pharmaceuticals Limited (SMSPHARMA) · Evonile Pharma Limited (NOVARTIND) · Gufic Biosciences Limited (GUFICBIO) · Zota Health Care Ltd. (ZOTA) · Kwality Pharmaceuticals Ltd (KPL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AARTIDRUGS in NSE Scanner →